ONO PHARMACEUTICAL CO.,LTD.

July 6, 2017

Array BioPharma Submits New Drug Applications to FDA for Binimetinib and Encorafenib in Advanced Melanoma

Boulder, Colo., (July 5, 2017) – Array BioPharma (Nasdaq: ARRY) announced the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The submissions are supported by data from the pivotal Phase 3 COLUMBUS study, which showed that patients who received binimetinib and encorafenib had a significantly longer progression free survival (PFS) compared to patients receiving vemurafenib.

Ono Pharmaceutical Co., Ltd. ("ONO") entered into the license agreement with Array BioPharma Inc. regarding binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor in May 2017 and received rights to develop and commercialize both products in Japan and South Korea.

Binimetinib and encorafenib are currently in two global Phase 3 clinical trials for the treatment of patients with BRAF-mutant melanoma (COLUMBUS study including Japan and South Korea) and BRAF-mutant colorectal cancer (BEACON CRC study including South Korea) as a combination therapy.

Please click here for the press release distributed by Array BioPharma Inc.

ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
Public_relations@ono.co.jp